Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study sought to determine if individuals with medically refractory migraine headache have volume or diffusion abnormalities on neuroimaging compared to neurotypical individuals.
Background: Neuroimaging biomarkers in headache medicine continue to be limited. Early prediction of medically refractory headache and migraine disorders could result in earlier administration of high efficacy therapeutics.
Methods: A single-center, retrospective, case control study was performed. All patients were evaluated clinically between 2014 and 2018. Individuals with medically refractory migraine headache (defined by ICDH-3 criteria) without any other chronic medical diseases were enrolled. Patients had to have failed more than two therapeutics and aura was not exclusionary. The initial MRI study for each patient was reviewed. Multiple brain regions were analyzed for volume and apparent diffusion coefficient values. These were compared to 81 neurotypical control patients.
Results: A total of 79 patients with medically refractory migraine headache were included and compared to 74 neurotypical controls without headache disorders. Time between clinical diagnosis and neuroimaging was a median of 24 months (IQR: 12.0-37.0). Comparison of individuals with medically refractory migraine headache to controls revealed statistically significant differences in median apparent diffusion coefficient (ADC) in multiple brain subregions ( < 0.001). pair-wise analysis comparing individuals with medically refractory migraine headache to control patients revealed significantly decreased median ADC values for the thalamus, caudate, putamen, pallidum, amygdala, brainstem, and cerebral white matter. No volumetric differences were observed between groups.
Conclusions: In individuals with medically refractory MH, ADC changes are measurable in multiple brain structures at an early age, prior to the failure of multiple pharmacologic interventions and the diagnosis of medically refractory MH. This data supports the hypothesis that structural connectivity issues may predispose some patients toward more medically refractory pain disorders such as MH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237368 | PMC |
| http://dx.doi.org/10.3389/fneur.2022.898219 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An international prognostic index to predict the early chemoimmunotherapy failure of diffuse large B-cell lymphoma.
Ann Hematol
September 2025
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Approximately 30-40% of diffuse large B-cell lymphoma (DLBCL) patients will develop relapse/refractory disease, who may benefit from novel therapies, such as CAR-T cell therapy. Thus, accurate identification of individuals at high risk of early chemoimmunotherapy failure (ECF) is crucial. Methods.
View Article and Find Full Text PDFVNS treatment in super-refractory status epilepticus: report of two cases and systematic review of literature.
Neurol Sci
September 2025
Pediatric Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Background: super-refractory status epilepticus (SRSE) is a rare and severe neurological condition associated with high mortality and significant long-term morbidity. In many cases, conventional medical treatments prove ineffective, with wide use of off-label therapies.
Methods: two researchers conducted a review of the medical records of subjects who had undergone VNS implantation in our tertiary Centre.
Radiofrequency thermocoagulation for the treatment of refractory focal status epilepticus.
Epileptic Disord
September 2025
APHM, Timone Hospital, Epileptology and Cerebral Rhythmology, Marseille, France.
This case study reports the first documented use of stereoelectroencephalography (SEEG)-guided radiofrequency thermocoagulation (RFTC) to treat refractory status epilepticus (RSE). A 33-year-old woman with drug-resistant epilepsy and recurrent RSE underwent SEEG to define her epileptogenic zone. A new RSE started shortly before and continued during the SEEG exploration, being unresponsive to multiple antiseizure medications, vagal nerve stimulation, and corticosteroid therapy.
View Article and Find Full Text PDFFrom Evidence to Bedside: The Role of Short-Acting β-Blockers in Sepsis Care.
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Sepsis remains a leading cause of critical illness and mortality worldwide, driven by a dysregulated host response to infection and often complicated by persistent tachycardia and cardiovascular dysfunction. Increasing evidence implicates excessive sympathetic activation as a contributor to sepsis-related hemodynamic instability and myocardial injury, prompting growing interest in the use of β-adrenergic blockade as a therapeutic adjunct. This review synthesizes current data on the safety and efficacy of short-acting, cardioselective β-blockers (BBs), particularly esmolol and landiolol, in septic shock.
View Article and Find Full Text PDFJAK1 Inhibition with Upadacitinib in a Patient with Refractory Severe Chronic Spontaneous Urticaria and Concomitant Rheumatoid Arthritis: Complete Resolution of Urticaria and Remission of Rheumatoid Arthritis.
Acta Derm Venereol
September 2025
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Medicine A, Assuta Ashdod University Hospital, Ashdod, Israel.